Nuveen’s Crescent Biopharma CBIO Stock Holding History

Nuveen’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$857K	Buy	+47,629	New	+$930K	﹤0.01%	3018
2021 Q2	–	Sell	-10,591	Closed	-$3.19M	–	3439
2021 Q1	$3.19M	Buy	10,591 +6,685	+171%	+$2.39M	﹤0.01%	2391
2020 Q4	$1.47M	Buy	3,906 +483	+14%	+$169K	﹤0.01%	2659
2020 Q3	$1.05M	Buy	3,423 +1,896	+124%	+$725K	﹤0.01%	2666
2020 Q2	$575K	Buy	1,527 +200	+15%	+$56.6K	﹤0.01%	2845
2020 Q1	$302K	Sell	1,327 -13	-1%	-$4.97K	﹤0.01%	2926
2019 Q4	$709K	Hold	1,340	–	–	﹤0.01%	2807
2019 Q3	$577K	Sell	1,340 -78	-6%	-$50.2K	﹤0.01%	2894
2019 Q2	$1.69M	Buy	+1,418	New	+$1.7M	﹤0.01%	2511

Other funds holding CBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nuveen's CBIO Position: Q2 2026 in Review

Nuveen opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 47,629 shares worth $857K. The stake represents ﹤0.01% of the portfolio and ranks #3018 among its holdings. This is a return to the name: Nuveen previously reported a position in CBIO as recently as Q1 2021.

Nuveen first reported a position in CBIO in Q2 2019 and has held it in 9 quarters since. The position peaked at $3.19M in Q1 2021. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

Nuveen held 47,629 shares of Crescent Biopharma worth $857K as of Q2 2026.
Crescent Biopharma was a new Nuveen position in Q2 2026.
Crescent Biopharma made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3018 holding.
Nuveen first reported a position in Crescent Biopharma in Q2 2019 and has held it in 9 quarters since.
Nuveen's Crescent Biopharma position peaked at $3.19M in Q1 2021.
82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.